Prevention of Typhoid Fever by Existing Improvements in Household Water, Sanitation, and Hygiene, and the Use of the Vi Polysaccharide Typhoid Vaccine in Poor Urban Slums: Results from a Cluster-Randomized Trial

Justin Im,†† Farhana Khanam,† Faisal Ahmmed,‡ Deok Ryun Kim,¹ Sophie Kang,¹ Birkneh Tilahun Tadesse,¹ Fahima Chowdhury,¹ Tasnuva Ahmed,² Asma Binte Aziz,¹ Masuma Hoque,² Md. Taufiqul Islam,² Juyeon Park,¹,³ Xinxue Liu,⁴ Dipika Sur,⁵ Gideok Pak,¹ Hyon Jin Jeon,¹,³ Khalequ Zaman,² Ashraful Islam Khan,² Firdausi Qadri,² Florian Marks,¹,³,⁶ Jerome H. Kim,¹ and John D. Clemens¹,²,⁷

¹International Vaccine Institute, Seoul, Republic of Korea; ²International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; ³Department of Medicine, University of Cambridge, Cambridge, United Kingdom; ⁴Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom; ⁵National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal, India; ⁶University of Antananarivo, Antananarivo, Madagascar; ⁷University of California Los Angeles Fielding School of Public Health, Los Angeles, California

Abstract. Modest improvements in household water, sanitation, and hygiene (WASH) and typhoid vaccination can reduce typhoid risk in endemic settings. However, empiric evaluation of their combined impact is lacking. A total of 62,756 persons residing in 80 clusters in a Kolkata slum were allocated randomly 1:1 to either the typhoid Vi polysaccharide vaccine (ViPS) or hepatitis A (Hep A) vaccine. Surveillance was conducted for 2 years before and 2 years after vaccination. We classified households as having “better” or “not better” WASH, and calculated the prevalence of better WASH households in clusters using previously validated criteria. We evaluated the protection by better household WASH, better household WASH prevalence, and ViPS vaccination against typhoid in all cluster members present at baseline using Cox proportional hazard models. Overall, ViPS vaccination was associated with a 55% (P < 0.001; 95% CI, 35–69) reduction of typhoid risk and was similar regardless of better WASH in the residence. Living in a better WASH household was associated with a typhoid risk reduction of 31% (P = 0.16; 95% CI, –16 to 59) overall. The reduction was 48% (P = 0.05; 95% CI, –7 to 73) in Hep A clusters. 6% (P = 0.85; 95% CI, –82 to 51) in ViPS clusters, and 57% (P < 0.05; 95% CI, 15–78) in the population during the 2 years preceding the trial. These findings demonstrate a preventive association of better household WASH in the non-ViPS population, but, unexpectedly, an absence of additional protection from ViPS by better WASH in the ViPS population. This analysis highlights the importance of assessing the combination of WASH in conjunction with typhoid vaccines, and has implications for the evaluation of new-generation typhoid conjugate vaccines.

INTRODUCTION

Typhoid fever, an invasive bloodstream infection caused by Salmonella enterica serovar Typhi, remains a significant public health problem.¹–⁴ Globally, there are approximately 12 million cases and 128,000 deaths each year, with almost all of the burden concentrated in low- and middle-income countries.⁵ Infection occurs through ingestion of contaminated food or water, and transmission can be high in areas with an insufficient clean water infrastructure and limited access to sanitary facilities. We know that major improvements in municipal water, sanitation, and hygiene (WASH) have drastically reduced infectious disease transmission, including typhoid, and have prevented disease in affluent countries.⁶ Empiric evidence from a Kolkata urban slum has demonstrated that improvements in household WASH occurring naturally, without a specific intervention, were predictive of reduced typhoid risk.⁷ Several effective typhoid vaccines are now licensed and available, including two that are WHO prequalified: a vaccine consisting of Vi polysaccharide (ViPS) and one that is ViPS conjugated chemically to a tetanus toxoid.⁸ Recognizing that current recommendations for control of typhoid in low- and middle-income countries emphasize the use of both effective typhoid vaccines and improvement of WASH,⁹ we asked whether protection by an effective typhoid vaccine acted independently of protection conferred by better existing WASH, and whether these independent effects were complementary when implemented together in an urban slum where typhoid is endemic. A cluster-randomized trial of an effective typhoid vaccine, ViPS, conducted in an urban slum of Kolkata, India, provided a unique platform to address these questions.

METHODS

Trial and population. We conducted a cluster-randomized, controlled trial of typhoid ViPS vaccine in an urban slum in Kolkata, India, conducted between 2004 and 2006.¹⁰ Demographic information and household WASH characteristics were collected from the trial population during a census conducted just before vaccination (baseline). All 62,756 individuals residing in the study area at baseline were included in the analysis. Individuals migrating into the study area and births occurring during the 2-year surveillance period were excluded.

Vaccination. Eighty clusters were assigned randomly to two groups of 40 clusters and received either a single-dose ViPS typhoid vaccine (Typherix, GSK) or a single-dose inactivated hepatitis A (Hep A) vaccine (Havrix, GSK). The vaccines were administered to participants who were 24 months and older. For this randomization, clusters were stratified by ward, size of population 18 years or younger, and size of population older than 18 years. Vaccination occurred between November 27 and December 31, 2004. Of 61,280 age-eligible individuals, 37,673 were vaccinated: 18,869 in...
the ViPS vaccine arm and 18,804 in the Hep A arm. The trial was masked at four levels: participant, care provider, investigator, and outcomes assessors.

**Clinical surveillance.** Passive surveillance for typhoid fever was conducted for 2 years after vaccination. In addition, as reported elsewhere, identical methods of demographic, WASH, and clinical surveillance were conducted in the 57,949 residents of all ages in the study area, none of whom had received either study vaccine during the 2 years before the inception of the vaccine trial. Residents of the study area presenting to one of five study clinics with a febrile episode underwent blood culture. A febrile episode was defined as a history of fever for at least 3 days and sequential visits, where date of discharge and subsequent date of fever onset were separated by 14 days or fewer were considered to be a single episode. Typhoid fever was defined as a febrile episode in which *Salmonella enterica* serovar Typhi was isolated from one or more blood cultures, and a home visit conducted within 7 days after discharge confirmed that the person whose name was given at the surveillance site had indeed sought care on the date of presentation.

**Definition of WASH.** As described previously, household WASH characteristics were collected during a baseline census of the trial population. Using these data, we developed a composite dichotomous (better, not better) household WASH variable comprising several WASH features that predicted typhoid risk independent of household socioeconomic status. A better WASH household was defined based on criteria using the following variables: having a drinking water source from a private tap, well, or pump; always washing hands with soap after defecation; having a private or shared flush toilet; and using filtered or boiled water for daily household use (Figure 1).

**Analytical approach.** We evaluated the overall ViPS vaccine protection against typhoid by comparing rates of blood culture-confirmed typhoid fever among all residents, vaccinated or not, of ViPS clusters versus all residents of Hep A clusters. Correspondingly, we evaluated the protection associated with better WASH in the household by comparing rates of typhoid in all members of better WASH households versus not better WASH households. Last, we assessed the protection associated with the prevalence of better WASH households in the clusters by comparing rates of typhoid in members of households in clusters with lower prevalence versus those in clusters with higher prevalence. To explore these associations further, we undertook analyses of overall ViPS protection of individuals by better versus not better WASH of the households in which they lived, as well as by the prevalence of better WASH households of the clusters in which they resided, and evaluated evidence for a modifying effect of WASH on ViPS protection and vice versa. To evaluate even further the impact on typhoid of living in a better versus not better WASH household, as well as the impact of living in a cluster with a greater versus lesser prevalence of better WASH in the household, we examined these associations separately for the clusters assigned to ViPS and those assigned to Hep A.

**Statistical analysis.** Simple associations of typhoid risk between groups were assessed using a $\chi^2$ test for heterogeneity. To measure the protection by ViPS in models, we used Cox proportional hazard regression analysis after evaluating proportionality assumptions for independent variables. Time zero at follow-up was considered the day of vaccination for vaccine recipients, and the median day of vaccination in the cluster of residence for unvaccinated persons. For individuals present at time zero, follow-up continued for 2 years until the study end date on Dec 30, 2006, the first typhoid

**FIGURE 1.** Decision tree for categorization of “better” and “not better” household water, sanitation, and hygiene (WASH) based on four dichotomous WASH variables.
episode, outmigration, or death, whichever occurred first. As described earlier, typhoid surveillance also was performed for the population in the trial area during the 2 years leading up to the trial. Classification of WASH of the households during this lead-in period was performed in a manner identical to that used for the trial, using information from a baseline census conducted before inception of surveillance, and the follow-up of this closed cohort was conducted in the same manner as the follow-up of subjects assembled at the onset of the trial. In individuals with multiple typhoid episodes, only the first episode was considered in the analysis. Models were adjusted for the variables used to define strata for randomization. Additional covariates (age, gender, Hindu religion, household population size, monthly household expenditures, distance to the nearest treatment center [above the median]) were selected with a forward stepwise algorithm based on a significance level of \( P < 0.05 \). An interaction term between household WASH and ViPS cluster assignment and good WASH prevalence and ViPS cluster assignment, respectively, was introduced into models to evaluate the presence of modifying effects. The protective effectiveness of ViPS, better WASH in the household, and prevalence of better WASH in households in the cluster was calculated as \((1 - \text{Hazard ratio}) \times 100\), where the hazard ratio was estimated by exponentiation of the coefficient for the relevant variable in the model, and the 95% CI for the hazard ratio was estimated using a robust sandwich method to account for the design effect of cluster randomization for the trial population. The analysis was performed using the “survival” package for the Cox model, the “car” package for collinearity, and the “dplyr” package for data management in R-Studio analytical software.11–13

**RESULTS**

**Assembly of the trial population.** In total, 62,756 individuals, of whom 61,280 were age-eligible to receive a vaccine, residing in 80 clusters, were present at the baseline census just before inception of the trial, and clusters were assigned randomly with equal probability to receive either ViPS (\( n = 31,075 \)) or a control (\( n = 31,681 \)) (Figure 2). There were 178 confirmed typhoid episodes recorded during follow-up, 50 cases in the ViPS clusters and 128 cases in the Hep A clusters. Within the ViPS clusters, 10 cases occurred in better WASH households and 40 cases in not better WASH households; in Hep A clusters, nine cases occurred in better WASH households and 119 cases in not better WASH households (Figure 2). With the exception of better WASH in the household, the treatment arms were well balanced with respect to the baseline characteristics, although several variables showed statistically significant differences as a result of the large sample size for the study (Table 1).

**Overall preventive impact of residence in the ViPS vaccine clusters, member of a better WASH household, and residence in a household in clusters with greater WASH prevalence.** Vaccine coverage was 61% (18,869 of 31,075) in ViPS clusters and 59% (18,804 of 31,681) in Hep A clusters. The prevalence of better WASH households was 26% (1,455 of 5,685) in ViPS clusters and 18% (1,044 of 5,824) in Hep A clusters (Table 1). The incidence of typhoid fever in members of ViPS clusters was 0.84/1,000 person-years, and in Hep A clusters was 2.12/1,000 person-years (\( P < 0.001 \); Table 2). Residence in ViPS clusters was associated with an overall adjusted protective effectiveness of 55% (\( P < 0.001 \); 95% CI, 35–69) against typhoid (Table 2).

**FIGURE 2.** CONSORT diagram showing the population at the first census and incident typhoid cases in Vi polysaccharide (ViPS) and hepatitis A (Hep A) vaccine clusters classified by residence in better or not better water, sanitation, and hygiene (WASH) household.
The incidence of typhoid fever in members of better WASH households was 0.77/1,000 person-years; and in not better WASH households, the incidence was 1.67/1,000 person-years (P = 0.001). Residence in a better WASH household was associated with an overall adjusted protective effectiveness of 31% (P = 0.16; 95% CI, 16 to 59 among residents of all clusters (Table 2). Evidence for an interaction between household WASH and ViPS was not observed (P = 0.331).

The incidence of typhoid fever in members of households in the lower tertile of better WASH household prevalence was 2.07/1,000 person-years; in the middle tertile, incidence was 1.41/1,000 person-years; and in the upper tertile, incidence was 0.99/1,000 person-years (P < 0.001). Relative to the lower tertile of better WASH household prevalence, residence in the middle tertile was associated with an adjusted protective effectiveness of 17% (P = 0.43; 95% CI, −32 to 48); residence in the upper tertile was associated with an adjusted protective effectiveness of −19% (P = 0.49; 95% CI, −96 to 27). In models that expressed better WASH prevalence on a continuous scale, each 1% increase in better WASH prevalence was associated with an adjusted protective effectiveness of −0.02% (P = 0.98; 95% CI, −1.43 to 1.37) (Table 2). Evidence for an interaction between better WASH coverage and ViPS was not observed (P = 0.222).

**Incidence of typhoid by vaccination and household WASH status.** Typhoid incidence was lowest in members of ViPS clusters residing in households with better WASH (0.68/1,000 person-years), highest in members of Hep A clusters residing in households with not better WASH (2.37/1,000 person-years), and intermediate in members of ViPS clusters residing in not better WASH households (0.89/1,000 person-years) and in members of Hep A clusters residing in better WASH households (0.89/1,000 person-years, P < 0.001 for heterogeneity of incidence in the four groups) (Tables 3 and 4).

**Protection by vaccine assignment in the cluster of residence according to better WASH in the household and prevalence of better WASH in the clusters.** In members of better WASH households, residence in ViPS clusters was associated with an adjusted protective effectiveness of 58% (P < 0.05; 95% CI, 14–79). Similarly, in members of not better WASH households, residence in ViPS clusters was associated with an adjusted protective effectiveness of 61% (P < 0.001; 95% CI, 44–73) (Tables 3 and 4). Residence in the ViPS clusters was associated with an adjusted protective effectiveness of 67% (P < 0.01; 95% CI, 27–85) for clusters in the lowest tertile of better WASH prevalence, 48% (P < 0.05; 95% CI, 6–71) in the middle tertile, and 50% (P < 0.05; 95% CI, 10–73) in the highest tertile (Tables 5 and 6).

**Protective impact of better WASH in the household and prevalence of better WASH in the clusters according to vaccine assignment of the cluster of residence.** In ViPS clusters, residence in a better WASH household failed to show a protective association with the risk of typhoid

### Table 1

Baseline comparability between Vi polysaccharide and hepatitis A clusters for analyses of overall vaccine protection by Vi polysaccharide

| Variable | Hep A cluster | ViPS cluster | P value |
|----------|---------------|--------------|---------|
| better WASH households, n (%) | 1,044 (18) | 1,455 (26) | < 0.001 |
| Age, y at baseline: mean ± SD | 28.1 ± 18.2 | 28.7 ± 18.3 | < 0.001 |
| Male gender, n (%) | 17,111 (54) | 16,680 (54) | 0.406 |
| Hindu religion, n (%) | 16,878 (53) | 18,794 (61) | < 0.001 |
| Household members, mean ± SD | 7.2 ± 3.8 | 7.3 ± 4 | 0.001 |
| Expenditure,* mean ± SD | 3,504.5 ± 2,432.3 | 3,531.1 ± 2,206.6 | 0.152 |
| Treatment center distance greater than median, †; m; n (%) | 16,516 (52) | 14,859 (48) | < 0.001 |

*Expenditure calculated as average monthly expenditures in Indian rupees.
† Distance measured in meters as the minimum straight-line distance from a household to the closest study center.

### Table 2

Protective effectiveness of Vi polysaccharide vaccine; better household water, sanitation, and hygiene; and better household water, sanitation, and hygiene prevalence against typhoid

| Variable | n | PY | Typhoid cases, n | IR (per 1,000 PY) | Crude PE, % (95% CI) | Adjusted* PE, % (95% CI) |
|----------|----|----|----------------|------------------|------------------|---------------------|
| ViPS vaccine cluster | 31,075 | 59,397 | 50 | 0.84 | 60%† (39–74) | 55† (35–69)‡ |
| Hep A vaccine cluster | 31,681 | 60,387 | 128 | 2.12 | | |
| better WASH households | 12,937 | 24,724 | 19 | 0.77 | 54%§† (22–73) | 31 (–16 to 59)§ |
| Not better WASH households | 49,819 | 95,059 | 159 | 1.67 | | |
| better WASH prevalence (lower tertile)** | 20,486 | 39,063 | 81 | 2.07 | Ref. | Ref. |
| better WASH prevalence (middle tertile)** | 21,164 | 40,306 | 57 | 1.41 | 32 (–17 to 60) | 17 (–32 to 48)† |
| better WASH prevalence (upper tertile)** | 21,106 | 40,414 | 40 | 0.99 | 52§ (19–72) | –19 (–96 to 27)† |

*All models were adjusted for cluster stratification variables (ward [wards 29 and 30], number of residents ≤18 years [<200 persons], ≥200 persons); number of residents >18 years (<500 persons, ≥500 persons), design effect, and selected covariates.
† P < 0.001.
‡ Model adjusted for the covariates household WASH, age, Hindu religion, and longer distance to the nearest treatment center than median.
§ P < 0.01.
‖ Model adjusted for the covariates vaccine assignment, age, Hindu religion, and longer distance to the nearest treatment center than median.
In Hep A clusters, relative to residence in the middle tertile was associated with an adjusted protective effectiveness of 25% (P = 0.39; 95% CI, 0.39–0.61), and residence in the upper tertile was associated with an adjusted protective effectiveness of −5% (P = 0.87; 95% CI, −86 to 41) (Tables 5 and 6). In models that expressed better WASH prevalence on a continuous scale, in ViPS clusters, each 1% increase in better WASH prevalence was associated with an adjusted protective effectiveness of −0.58% (P = 0.55; 95% CI, −2.50 to 1.30), whereas in Hep A clusters, each 1% increase was associated with an adjusted protective effectiveness of 0.96% (P = 0.33; 95% CI, −1.00 to 2.88) (Tables 5 and 6). The presence of collinearity prevented simultaneous assessment of household WASH and household WASH prevalence.

### Table 3

| WASH status | VIPS cluster | Hep A cluster | VIPS PE |
|-------------|--------------|---------------|--------|
| n | Vy | Typhoid (IR per 1,000 Vy) | n | Typhoid (IR per 1,000 Vy) | Crude PE, % (95% CI) | Adjusted* PE, % (95% CI) |
| Not better | 23,407 | 44,755 | 40 (0.89) | 26,122 | 50,304 | 119 (2.37) | 62† (44–75) | 61† (44–73)† |
| better | 7,668 | 14,642 | 10 (0.68) | 5,269 | 10,082 | 9 (0.06) | 23 (–108 to 72) | 58§ (14–79)§ |

† Model adjusted for the covariates age, household population size, and monthly household expenditures.
‡ Model adjusted for the covariates age, household population size, and longer distance to the nearest treatment center than median.
§ Model adjusted for the covariates age, household population size, and residence in the nearest treatment center than median.

### Table 4

| WASH status | VIPS cluster | Hep A cluster |
|-------------|--------------|---------------|
| n | Vy | Typhoid (IR per 1,000 Vy) | n | Typhoid (IR per 1,000 Vy) |
| Not better | 23,407 | 44,755 | 40 (0.89) | 26,122 | 50,304 | 119 (2.37) |
| better | 7,668 | 14,642 | 10 (0.68) | 5,269 | 10,082 | 9 (0.06) |

† Model adjusted for the covariates age, household population size, and residence in the nearest treatment center than median.
‡ Model adjusted for the covariates age, household population size, and longer distance to the nearest treatment center than median.
§ Model adjusted for the covariates age, household population size, and residence in the nearest treatment center than median.

### Table 5

| WASH prevalence | VIPS cluster | Hep A cluster | VIPS PE |
|-----------------|--------------|---------------|--------|
| n | Vy | Typhoid (IR per 1,000 Vy) | n | Typhoid (IR per 1,000 Vy) | Crude PE, % (95% CI) | Adjusted* PE, % (95% CI) |
| Lower tertile† | 7,673 | 14,612 | 9 (0.62) | 12,813 | 24,452 | 72 (2.94) | 79† (62–89) |
| Middle tertile† | 9,615 | 18,394 | 19 (1.03) | 11,549 | 21,912 | 38 (1.73) | 40 (–19 to 70) |
| Upper tertile† | 13,787 | 26,381 | 22 (0.83) | 7,319 | 14,023 | 18 (1.28) | 35 (–27 to 67) |

† Model adjusted for the covariates age, household population size, and residence in the upper tertile was associated with an adjusted protective effectiveness of −5% (P = 0.87; 95% CI, −86 to 41) (Tables 5 and 6). In models that expressed better WASH prevalence on a continuous scale, in ViPS clusters, each 1% increase in better WASH prevalence was associated with an adjusted protective effectiveness of −0.58% (P = 0.55; 95% CI, −2.50 to 1.30), whereas in Hep A clusters, each 1% increase was associated with an adjusted protective effectiveness of 0.96% (P = 0.33; 95% CI, −1.00 to 2.88) (Tables 5 and 6). The presence of collinearity prevented simultaneous assessment of household WASH and household WASH prevalence.

### Table 6

| Protective effectiveness | VIPS cluster, % (95% CI) | Hep A cluster, % (95% CI) |
|--------------------------|--------------------------|--------------------------|
| Middle vs. lower | Crude PE | −68 (−231 to 15) | 41 (−9 to 68) |
| Adjusted PE | −50 (−177 to 19) | 25 (−45% to 61) |
| Upper vs. lower | Crude PE | −35 (−175 to 33) | 56 (24–75)† |
| Adjusted PE | −55 (−303 to 40) | 56 (24–75)† |

† Model adjusted for the covariates age, household population size, and residence in the nearest treatment center than median.
‡ Model adjusted for the covariates age, household population size, and longer distance to the nearest treatment center than median.
§ Model adjusted for the covariates age, household population size, and residence in the nearest treatment center than median.

* Model adjusted for the covariates age and monthly household expenditures.
Further evaluation of the association of better WASH in the household and typhoid risk in a population not vaccinated with ViPS. Because the association between better WASH in household and the risk of typhoid in household residents in the Hep A clusters was of borderline statistical significance \( P = 0.05 \), we assessed the relationship in the 57,949 unvaccinated residents of the study area monitored during the 2 years before the inception of the vaccine trial. These residents were assessed with the same procedures and with the same data collection instruments (including the same definition of better WASH in the household) as those used during the trial. During this lead-in period, the incidence of typhoid fever in members of better WASH households was 0.46/1,000 person-years; in not better households, incidence was 1.36/1,000 person-years \( (P < 0.05) \). After adjusting for potential confounding variables, a 57% reduction of typhoid risk was observed in residents of households with better WASH compared with residents in households with not better WASH \( (P < 0.05; 95\% \text{ CI}, 15–78) \).

**DISCUSSION**

In this trial, living in a cluster vaccinated with ViPS was associated with protection against typhoid, and the level of protection was similar regardless of whether the individual lived in a household with better WASH. Conversely, living in a better WASH household was associated with suggestively reduced typhoid risk among members of all the clusters, but this reduction was only evident in clusters that received Hep A—a finding consistent with protection observed in members of households with better WASH in the population monitored for the 2 years of surveillance preceding the trial. A greater prevalence of better WASH households in the cluster was not associated with a reduced typhoid risk overall in all clusters, nor was it seen in the ViPS and Hep A clusters considered separately.

Before discussing the implications of these findings, it is important to consider the limitations of our study. First, our variable classifying households as having better or not better WASH was constructed using simple variables collected at baseline, which may not have fully captured or might not have served as proxies for the WASH behaviors and facilities responsible for the reduction of risk of typhoid in the household. As a result, our household WASH classification variable may have underestimated the true impact of household WASH against typhoid. Second, our definition of better WASH may be idiosyncratic to the population under study and may not be generalizable to other settings. Nonetheless, our findings support the concept that better WASH in the household occurring spontaneously without external intervention was associated with a reduced risk of typhoid in the slums participating in the trial. Third, although the trial cluster-randomized vaccination, it did not randomize WASH. However, we controlled for potentially confounding variables in our analyses. Fourth, because of the collinearity of household-level WASH and neighborhood WASH prevalence, it was not possible to evaluate the independent protection associated with these two variables when both were considered simultaneously in our analyses. Last, our findings, although elucidating the separate and joint impacts of ViPS and WASH in the setting for the study, may or may not apply to other settings that have different WASH practices or to different typhoid vaccines.

Our analyses also have several important strengths. The analyses were conducted on data collected in the context of a prospective cluster-randomized trial of a well-defined population under comprehensive follow-up for typhoid. It used a previously developed and validated definition of better household WASH. In addition, typhoid was detected with clear clinical criteria, including blood culture confirmation, and diagnoses were made without knowledge of either vaccination or household WASH status.

Our analyses produced two unexpected observations. First, the protective association of better household WASH was absent in clusters assigned to ViPS, suggesting no additional benefit of WASH in a vaccinated population. That living in a household with better WASH was not associated with a lower risk of typhoid in clusters targeted for ViPS, but was in those targeted for Hep A, might be related to the observation that ViPS was shown earlier to confer substantial herd protection in this trial, reflecting a reduction of the intensity of typhoid transmission in the ViPS clusters.10 It is possible that the reduction of typhoid transmission in the better WASH households resulted in less of a reduction of typhoid disease incidence in the lower transmission settings of the ViPS clusters, as evidenced by the shape of the curve relating the size of the ingested inoculum of typhoid and the risk of typhoid disease.14 However, because the interaction term between ViPS and WASH variables in this analysis was not significant, lack of statistical heterogeneity indicates that apparent differences in typhoid risk in the vaccine groups may rather be a result of random variation and small sample size, and not the modification of WASH effects by vaccination status. Second, protection associated with ViPS was similar regardless of household WASH status. We anticipated that the protective association of better household WASH, mediated by reducing exposure to the infectious agent within the household, would enhance the protective effects of the vaccine. However, this observation may be consistent with the similar levels of ViPS protection recorded in randomized trials done in Nepal, South Africa, and China15–17—sites with different rates of typhoid infection, possibly mimicking settings where exposure to typhoid varies as a result of the presence or absence of improved WASH.

In aggregate, our findings suggest that minor improvements in WASH, which already existed within this poor urban slum study setting and are therefore affordable and attainable, were associated with a substantial reduction in the risk of typhoid in the population that had not received an effective typhoid vaccine. However, these improvements failed to reduce further the risk of typhoid in a population that had received an effective typhoid vaccine. Although our observations do not argue against possible combined protection against endemic typhoid by well-designed WASH interventions and effective typhoid vaccines, our data do not support the assertion that naturally occurring improvements of household WASH added to the protection by ViPS vaccine in this urban slum setting. Although ViPS is no longer the primary recommended vaccine for developing countries, our unexpected results underscore the importance of evaluating the combined and independent effects of WASH and effective typhoid vaccines—in particular, Vi conjugate vaccines—which are now approved and recommended for use in endemic settings.
Financial support: This publication was made possible through a grant from the Bill & Melinda Gates Foundation (INV-025386).

Authors’ addresses: Justin Im, Deok Ryun Kim, Sophie Kang, Birkhe Tila Tadesse, Asma Binte Aziz, Gideok Pak, Jerome H. Kim, International Vaccine Institute, Seoul, Republic of Korea, E-mails: justin.im@ivi.int, drkim@ivi.int, sophie.kang@ivi.int, birkhe.tadesse@ivi.int, asma.aziz@ivi.int, gdipak@ivi.int, and jerome.kim@ivi.int. Farhana Khanam, Faisal Ahmmed, Fahima Chowdhury, Tasnuva Ahmed, Masuma Hoque, Md. Taufiquil Islam, Khalequ Zaman, Ashraful Islam Khan, and Firdausi Qadri, International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh, E-mails: farhanak@icddrb.org, faisal.ahmmed@icddrb.org, fchowdhury@icddrb.org, tasnuva.ahmed@icddrb.org, masuma.hoquie@icddrb.org, taufiquislam@icddrb.org, kzaman@icddrb.org, ashrakf@icddrb.org, and fqadri@icddrb.org. Juyeon Park and Hyon Jin Jeon, International Vaccine Institute, Seoul, Republic of Korea, and Department of Medicine, University of Cambridge, Cambridge, UK, E-mails: juyeon.park@ivi.int and hyonjin.jeon@ivi.int. Xinxue Liu, Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK, E-mail: xinxue.liu@paediatrics.ox.ac.uk. Dipika Sur, National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal, India, E-mail: dipikasur@hotmail.com. Florian Marks, International Vaccine Institute, Seoul, Republic of Korea, Department of Medicine, University of Cambridge, Cambridge, UK, and University of Antananarivo, Antananarivo, Madagascar, E-mail: fmarks@ivi.int. John D. Clemens, International Vaccine Institute, Seoul, Republic of Korea, International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh, and University of California Los Angeles Fielding School of Public Health, Los Angeles, CA, E-mail: john.clemens@ivi.int.

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Tack B et al., 2019. Salmonella typhi from blood cultures in the Democratic Republic of the Congo: a 10-year surveillance. Nephrol Dial Transplant 68: S130–S137.

2. Mogasale V et al., 2014. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health 2: e570–e580.

3. Antilllon M et al., 2017. The burden of typhoid fever in low- and middle-income countries: a meta-regression approach. PLoS Negl Trop Dis 11: e0005376.

4. Kim JH, Mogasale V, Im J, Ramani E, Marks F, 2017. Updated estimates of typhoid fever burden in sub-Saharan Africa. Lancet Glob Health 5: e969.

5. Collaborators GTaP. 2019. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis.

6. Cutler D, Miller G, 2005. The role of public health improvements in health advances: the twentieth-century United States. Demography 1: 1–22.

7. Im J et al., 2020. Can existing improvements of water, sanitation, and hygiene (WASH) in urban slums reduce the burden of typhoid fever in these settings? Nephrol Dial Transplant.

8. World Health Organization, 2017. Typhoid Vaccine Prequalified. Available at: https://www.who.int/medicines/news/2017/WHOprequalifies-breakthrough-typhoid-vaccine/en/. Accessed January 3, 2018.

9. World Health Organization, 2018. Typhoid Vaccines: WHO Position Paper—March 2018. Geneva, Switzerland: WHO.

10. Sur D et al., 2009. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 361: 335–344.

11. Robin X et al., 2011. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12: 77.

12. Terry M, Therneau PMG, 2000. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer.

13. Hadley Wickham RF, Henry L, Müller K, 2018. dplyr: A Grammar of Data Manipulation.

14. Dupont HL, Hornick RB, Snyder MJ, Dawkins AT, Heiner GG, Woodward TE, 1971. Studies of immunity in typhoid fever: protection induced by killed oral antigens or by primary infection. Bull World Health Organ 44: 667–672.

15. Klugman KP et al., 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. N Engl J Med 317: 1104.

16. Acharya IL et al., 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. N Engl J Med 317: 1101–1104.

17. Yang HH et al., 2001. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 79: 625–631.